Mode
Text Size
Log in / Sign up

FANCI overexpression linked to poor prognosis in multiple cancers, review findsProtein called FANCI may play role in cancer progression

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret FANCI overexpression as a potential prognostic marker and therapeutic target, but recognize the evidence is associative and preliminary.

This narrative review synthesizes current literature on FANCI (Fanconi anemia complement group I), a protein central to the Fanconi anemia pathway. The authors describe FANCI's established role in forming a stable heterodimer with FANCD2, which is critical for DNA damage response and repair. Additionally, FANCI is involved in ribosome biogenesis, meiosis, and mRNA export, highlighting its pleiotropic functions.

A key finding is that FANCI is overexpressed in various malignancies, and this overexpression is associated with tumor progression and poor prognosis. The review details regulatory mechanisms including phosphorylation and ubiquitination that control FANCI activity. The authors suggest that FANCI represents a potential therapeutic target in cancer, though this is based on associative evidence from the literature.

Limitations are not explicitly reported in the source, but the review's narrative nature and lack of pooled effect sizes mean the conclusions are qualitative. The evidence for FANCI as a therapeutic target is preliminary and requires further investigation in preclinical and clinical settings. Clinicians should interpret these findings cautiously, as they do not yet inform direct clinical practice.

How this fits prior evidence

This review extends prior coverage of cancer-related pathways by focusing on FANCI, a protein involved in DNA repair. While prior items addressed interventions like walking training for fatigue or surgical techniques for complications, this review highlights a molecular target. It contrasts with findings on depression prevalence or cancer mortality in transplant recipients by addressing a potential mechanism rather than an epidemiological or interventional outcome.

When our cells get damaged, they need a way to fix the broken parts. A specific protein called FANCI acts like a critical worker in this process. It helps repair DNA and manages how our cells build proteins and move information around. Because it is so vital for cell health, scientists are looking closely at how it behaves in different diseases.

Researchers found that while FANCI is necessary for normal life, it can also behave differently in cancer. In several types of tumors, this protein is overexpressed, which means the body produces too much of it. When this happens, it can help a tumor grow and spread more easily. This link between high levels of FANCI and poorer outcomes makes it an important area of study.

Because of its role in tumor growth, scientists have identified FANCI as a potential target for new treatments. While the research is currently based on reviewing existing literature, it highlights how specific proteins can influence whether a cancer progresses quickly or slowly.

What this means for you:
The protein FANCI helps repair DNA but may promote tumor growth when found in high amounts in certain cancers.

Common questions

What role does the FANCI protein play in the body?

FANCI is essential for your cells to function correctly. It forms a stable pair with another protein called FANCD2 to help repair DNA damage. Beyond repairing DNA, it also helps with making ribosomes, which are parts of the cell that build proteins, and helps move genetic information out of the cell nucleus.

How is FANCI linked to cancer?

In some types of cancer, the body produces too much FANCI. This overabundance can help tumors grow more quickly and spread. Because it is found in high amounts in various malignancies, researchers are looking at it as a potential target for new medical treatments.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Fanconi anemia complement group I (FANCI), a core component of the Fanconi anemia pathway, has emerged as a potential oncogenic factor across multiple cancer types. Located on chromosome 15q26.1, FANCI encodes a protein named FANCI that forms a stable heterodimer with FANCD2, playing a central role in the DNA damage response and repair. Beyond its involvement in DNA repair, FANCI participates in ribosome biogenesis, meiosis, and mRNA export, underscoring its essential role in maintaining genomic stability. Although FANCI deficiency has traditionally been associated with Fanconi anemia, recent studies have demonstrated that FANCI is overexpressed in various malignancies, where it promotes tumor progression and correlates with poor prognosis. The expression and activity of FANCI are tightly regulated at multiple levels, including transcriptional and post-transcriptional regulation by transcription factors and non-coding RNAs, as well as post-translational modifications such as phosphorylation mediated by PP2A and ATR, monoubiquitination catalyzed by the FANCL–UBE2T complex, and deubiquitination by USP1-UAF1. This review summarizes the functional mechanisms of FANCI across diverse physiological and pathological processes, highlighting its role as a crucial molecular bridge linking genomic stability maintenance to cancer development, and emphasizing its potential as a promising therapeutic target in cancer.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.